The European Medicines Agency (EMA) recommends that the European Commission approve a first drug that can delay the progression of type 1 diabetes in stage 3.
An estimated 2.2 million people in the EU live with type 1 diabetes and there are currently no approved treatments within the Union to delay or cure the disease.
The drug in question is manufactured by the pharmaceutical company Sanofi and goes by the name Teizeild. Following a review, the EMA now recommends that it be approved for use in adults and children from the age of eight with stage two type 1 diabetes.
The formal decision to approve the medicine is made by the European Commission.
In 2022, the drug was approved for use in the United States.
